Upstream Hormones: The Quiet Return of DHEA and Pregnenolone in Complex Chronic Care
Chronic disease rarely announces a single failure. It accumulates small regulatory distortions until physiology begins behaving like a misaligned orchestra. ...
The Diagnostic Mirror
Sometimes the most consequential medical discoveries arrive not as new drugs but as new ways of looking at familiar data. ...
Why Drug Prices Diverge at the Pharmacy Counter
The number printed on a pharmacy receipt often has the least to do with the drug itself. Prescription drug pricing ...
The Transparency Experiment
The modern American drug market was built on opacity, and then—suddenly—it was asked to explain itself. The Trump administration’s push ...
The Transparency Paradox
The assumption seems obvious: if prices are hidden, markets malfunction; reveal them, and competition will discipline costs. Healthcare policy in ...
The Long Tail of Telehealth
Telemedicine was once described as the future of healthcare; today it resembles something more complicated—an infrastructure whose permanence remains politically ...
The Economics of Pollen
Each spring, invisible clouds drift across large sections of the United States, triggering one of the most predictable—and underestimated—public health ...
The Premium Spiral
Every autumn, a familiar conversation unfolds inside corporate boardrooms and human resources departments across the United States: how much more ...
The Triple Agonist Moment
Few areas of modern medicine have transformed as quickly—or as unpredictably—as the pharmacology of metabolic disease. For decades, obesity pharmacotherapy ...
Common Data Breach Risks in the Healthcare Industry
Understand the common data breach risks in healthcare and how organizations can protect sensitive patient information from growing cybersecurity threats.
The Epidemiology of a Red Eye
Few medical symptoms generate as much immediate alarm for patients—and as much diagnostic ambiguity for clinicians—as a suddenly inflamed eye. ...
Why Drug Prices Diverge at the Pharmacy Counter
The number printed on a pharmacy receipt is often the least informative price in the pharmaceutical economy. Patients encounter that ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more